Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02728700

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This pilot phase I/II trial studies the side effects and how well sirolimus and mycophenolate mofetil work in preventing graft versus host disease (GvHD) in patients with hematologic malignancies undergoing hematopoietic stem cell transplant (HSCT). Biological therapies, such as sirolimus and mycophenolate mofetil, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Giving sirolimus and mycophenolate mofetil after hematopoietic stem cell transplant may be better in preventing graft-versus-host disease.

Status: 
Recruiting
Study Date: 
Mon, 02/01/2016 to Thu, 02/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Undergo HSCT Other Names: allogeneic stem cell transplantation HSC HSCT Other: Laboratory Biomarker Analysis Correlative studies Drug: Mycophenolate Mofetil Given IV Other Names: Cellcept MMF Drug: Sirolimus Given PO Other Names: AY 22989 RAPA Rapamune RAPAMYCIN SILA 9268A WY-090217